FTDI
NKTR icon

First Trust Direct Indexing’s Nektar Therapeutics NKTR Stock Holding History

First Trust Direct Indexing’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-234
Closed -$60K – 772
2020
Q4 		$60K Buy
+234
New +$60.5K 0.02% 700

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Direct Indexing's NKTR Position: Q1 2021 in Review

First Trust Direct Indexing sold out of Nektar Therapeutics (NKTR) in Q1 2021, closing a stake of 234 shares — an estimated $60K sold.

First Trust Direct Indexing first reported a position in NKTR in Q4 2020 and held it in 1 quarter. The position peaked at $60K in Q4 2020. 235 funds tracked by Wall St. Rank hold NKTR as of Q1 2021.

  • First Trust Direct Indexing reported no remaining Nektar Therapeutics position as of Q1 2021 after selling out during the quarter.
  • First Trust Direct Indexing sold 234 Nektar Therapeutics shares in Q1 2021, an estimated $60K.
  • First Trust Direct Indexing first reported a position in Nektar Therapeutics in Q4 2020 and held it in 1 quarter.
  • First Trust Direct Indexing's Nektar Therapeutics position peaked at $60K in Q4 2020.
  • 235 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2021.

Based on First Trust Direct Indexing's 13F filing for Q1 2021, filed 14 Apr 2021.